Skip to main content
All lobbying filings

F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES

Lobbying for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES

 Filing 2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 14, 2025
Expenses
$100,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 2
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 3
  • S 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
  • HR 1
    An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
  • HR 1108
    Diagnostics Testing Preparedness Plan Act of 2025
 Lobbying activity 4
Medicare/Medicaid

Access to and reimbursement of diagnostics in the Medicare program. Issues related to Medicare reimbursement of Clinical Laboratory Fee Schedule (CLFS), specifically reforms to address payment cuts resulting from the Protecting Access to Medicare Act (PAMA) 2014. Issues related to Medicare coverage and reimbursement for FDA-designated breakthrough medical devices, focusing on establishing transitional coverage period, including S.1717 The Ensuring Patient Access to Critical Breakthrough Products Act. Issues related to Corporate Tax and Tariffs, H.R.1 - One Big Beautiful Bill Act

Foreign Relations

(FOR) HIV Testing in the President's Emergency Plan for AIDS Relief, including funding to support PEPFAR laboratory services and testing in FY2026 Appropriations for National Security, Department of State, and Related Programs, and PEPFAR Reauthorization in the FY2026 State Department Reauthorization

Health Issues

(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness

Medical/Disease Research/Clinical Labs

(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Issues related to diagnostics to support Preeclampsia, Alzheimer's and Influenza Preparedness

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem